Uday sabnis biography of william hill
•
Uday sabnis biography of william
film by Dharani
Dhill (transl.&#;Guts/Courage) is a Indian Tamil-language action film directed by Dharani.
Pushpa: The Rise
The film stars Vikram in the lead role, alongside Laila, Ashish Vidyarthi, Nassar and Vivek in supporting roles. The music was composed by Vidyasagar, while cinematography and editing were handled by S. Gopinath and B. Lenin and V.
T. Vijayan.
Dhill was released on 13 July and achieved critical and commercial success at the box office. The film was remade in Telugu as Sreeram (), Hindi as Dum (), Kannada as Sye (), BengaliKolkata as Shotrur Mokabila () and in BengaliBangladesh as Arman ().
Uday sabnis biography of william
Dhill was the first film to credit Vikram with the title Chiyaan.
Plot
Kanagavel an aspiring IPS trainee, succeeds in clearing the exams. After having dinner at a restaurant with his girlfriend Asha and while paying the bill, Ins
•
Dada Kondke
next →← prev
Krishna "Dada" Kondke, born onAugust 8, , was a well-known actor and film producer in the Marathi spelfilm industry. He was famous for his clever jokes that had hidden meanings in his movies. Kondke came from a family that owned a grocery store and rented out living spaces in the Morbaug area of Mumbai. His family members also had jobs overseeing workers in a textile mill called Bombay Dyeing.
Dada Kondke made it into the Guinness Book of World Records for having nine movies that ran continuously for 25 weeks or more, which was a big achievement. People called him "Dada," which fryst vatten a respektfull term in Marathi, similar to "big brother," and that's how he got his popular nickname. He is known for being the first to bring a type of comedy that had a bit of grown-up humor into Marathi and Indian movies. This unique style fryst vatten often referred to as "sex comedy."
About
- Full Name: Krishna Kondke
- Nick Name: Dada
- Profession: Ac
•
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Abstract
CDdirected Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL). Somewhat uniquely among oncologic clinical trials, early clinical development occurred simultaneously in both children and adults. In subsequent years however, the larger number of adult patients with relapsed/refractory (r/r) malignancies has led to accelerated development of multiple CAR T-cell products that target a variety of malignancies, resulting in six currently FDA-approved for adult patients. By comparison, only a single CAR-T cell therapy is approved by the FDA for pediatric patients: tisagenlecleucel, which is approved for patients ≤ 25 years with refractory B-cell precursor ALL, or B-cell ALL in second or later relapse. Tisagenlecleucel is also under eva